Skip to main content

Table 3 First-choice drugs and combined protocols chosen by respondents for the treatment of proteinuria in the clinical scenarios of CanL stages IIb, III and III

From: Dogs with leishmaniosis: how are we managing proteinuria in daily practice? A Portuguese questionnaire-based study

First-choice drugs and combined protocols

LeishVet classification

Stage IIb (n = 14)

Stage III (n = 54)

Stage IV (n = 76)

a. First-choice drugsa

 ACEI

14 (100%)

46 (85.2%)

60 (78.9%)

 ARB

0%

5 (9.3%)

10 (13.2%)

 CCB

0%

2 (3.7%)

4 (5.3%)

 Antithrombotic therapy

0%

1 (1.9%)

2 (2.6%)

b. Single-drug and combined protocolsb

 ACEI

9 (64.3%)

22 (40.7%)

35 (46.1%)

 ACEI + NA

4 (28.7%)

7 (13.0%)

0%

 ACEI + aldosterone receptor blockers

0%

1 (1.9%)

1 (1.3%)

 ACEI + antithrombotic therapy

0%

6 (11.1%)

11 (14.5%)

 ACEI + ARB

1 (7.1%)

4 (7.4%)

9 (11.8%)

 ACEI + CCB

0%

2 (3.7%)

3 (3.9%)

 ACEI + ARB + antithrombotic therapy

0%

0%

3 (3.9%)

 ACEI + CCB + aldosterone receptor blockers

0%

0%

1 (1.3%)

 ACEI + other

0%

5 (9.3%)

2 (2.6%)

 SUM (ACEI with other compounds)

1 (7.1%)

18 (33.3%)

30 (39.5%)

 ARB

0%

4 (7.4%)

6 (7.9%)

 ARB + antithrombotic therapy

0%

1 (1.9%)

1 (1.3%)

 CCB

0%

0%

4 (5.3%)

 CCB + NA

0%

2 (3.7%)

0%

 SUM (protocols without ACEI)

0%

7 (12.9%)

11 (14.5%)

  1. ACEI angiotensin converting enzyme inhibitors angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, CCB Calcium channel blockers, NA no answer/not detailed
  2. aOnly one option available
  3. bOne or more options available